Cogent Biosciences (COGT) Operating Leases (2019 - 2026)

Cogent Biosciences' Operating Leases history runs 8 years deep, the most recent figure standing at $14.1 million for Q1 2026.

• In Q1 2026, Operating Leases fell 8.93% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (down 8.93% YoY), while the FY2025 annual figure was $14.4 million, down 9.73% from the prior year.
• Operating Leases was $14.1 million for Q1 2026 at Cogent Biosciences, down from $14.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $19.0 million in Q2 2022 to a low of $1.1 million in Q1 2022.
• Historically, Operating Leases has averaged $15.8 million across 5 years, with a median of $16.7 million in 2024.
• Biggest YoY gain for Operating Leases was 2093.26% in 2022; the steepest drop was 56.74% in 2022.
• A 5-year view of Operating Leases shows it stood at $18.2 million in 2022, then dropped by 4.16% to $17.5 million in 2023, then decreased by 8.96% to $15.9 million in 2024, then retreated by 9.73% to $14.4 million in 2025, then decreased by 1.8% to $14.1 million in 2026.
• The last three Operating Leases figures came in at $14.1 million (Q1 2026), $14.4 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.